San Rocco Therapeutics

San Rocco Therapeutics is a private, pre-revenue biotech firm with a deep historical lineage in hemoglobinopathy research, originating from founder Patrick Girondi's personal mission in the 1990s. The company is advancing a gene therapy platform, leveraging a vector from renowned researcher Michel Sadelain, to treat Sickle Cell Disease and Beta Thalassemia. Based in Cambridge, USA, and with a European presence, it operates as a virtual R&D company, collaborating extensively with academic and clinical institutions to advance its programs, which appear to be in pre-clinical or early clinical stages.

Gene therapy platform utilizing a lentiviral vector (from Michel Sadelain) for ex vivo modification of hematopoietic stem cells, with historical expertise in pharmacological fetal hemoglobin (gamma globin) reactivation using butyrate derivatives.

The gene therapy space for hemoglobinopathies is highly competitive, with approved products from Bluebird Bio and Vertex/CRISPR Therapeutics, and several other companies in clinical development. San Rocco appears to be an earlier-stage contender, competing on the basis of its specific vector technology and mission to achieve lower-cost manufacturing and treatment.